GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Mohanram G-Score

Emmaus Life Sciences (Emmaus Life Sciences) Mohanram G-Score : 3 (As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Mohanram G-Score?

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Emmaus Life Sciences has an G-score of 3.

The historical rank and industry rank for Emmaus Life Sciences's Mohanram G-Score or its related term are showing as below:

EMMA' s Mohanram G-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 3

During the past 13 years, the highest Piotroski G-score of Emmaus Life Sciences was 4. The lowest was 1. And the median was 3.


Emmaus Life Sciences Mohanram G-Score Historical Data

The historical data trend for Emmaus Life Sciences's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences Mohanram G-Score Chart

Emmaus Life Sciences Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 4.00 4.00 3.00 4.00

Emmaus Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 4.00 4.00 3.00

Competitive Comparison of Emmaus Life Sciences's Mohanram G-Score

For the Biotechnology subindustry, Emmaus Life Sciences's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmaus Life Sciences's Mohanram G-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Mohanram G-Score falls into.



Emmaus Life Sciences Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Emmaus Life Sciences has an G-score of 3.

Emmaus Life Sciences  (OTCPK:EMMA) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Emmaus Life Sciences Mohanram G-Score Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's Mohanram G-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Executives
Seah H. Lim director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee director, officer: Vice Chairman & COO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara director, 10 percent owner, officer: Chairman and CEO 20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi director 1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark officer: SVP, Clinical Development 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich officer: CIO & SVP 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood director 956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii officer: Chief Financial Officer 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato director 3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran officer: Chief Administrative Officer 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey director 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki officer: Sr. VP Finance 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501